201 related articles for article (PubMed ID: 21059726)
1. Population based screening for chronic kidney disease: cost effectiveness study.
Manns B; Hemmelgarn B; Tonelli M; Au F; Chiasson TC; Dong J; Klarenbach S;
BMJ; 2010 Nov; 341():c5869. PubMed ID: 21059726
[TBL] [Abstract][Full Text] [Related]
2. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review.
Yeo SC; Wang H; Ang YG; Lim CK; Ooi XY
Clin Kidney J; 2024 Jan; 17(1):sfad137. PubMed ID: 38186904
[TBL] [Abstract][Full Text] [Related]
4. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of School Urinary Screening for Early Detection of IgA Nephropathy in Japan.
Honda K; Akune Y; Goto R
JAMA Netw Open; 2024 Feb; 7(2):e2356412. PubMed ID: 38363568
[TBL] [Abstract][Full Text] [Related]
6. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study.
Kaur G; Chauhan AS; Prinja S; Teerawattananon Y; Muniyandi M; Rastogi A; Jyani G; Nagarajan K; Lakshmi P; Gupta A; Selvam JM; Bhansali A; Jain S
Lancet Public Health; 2022 Jan; 7(1):e65-e73. PubMed ID: 34774219
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.
Ramjee L; Vurgun N; Ngai C; Patel M; Tremblay G
Clinicoecon Outcomes Res; 2023; 15():213-226. PubMed ID: 37020570
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of population-based screening for microalbuminuria in people with type 2 diabetes mellitus in India.
Mathan Kumar S; Essakky S; Rajasulochana SR; Kar SS; Sivanatham P; Anandraj J; Parameswaran S; Soman B; Rajsekhar K; Stanley A
Int J Technol Assess Health Care; 2023 Nov; 39(1):e66. PubMed ID: 37960938
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain.
Villa G; Sánchez-Álvarez E; Cuervo J; Fernández-Ortiz L; Rebollo P; Ortega F
BMC Health Serv Res; 2012 Aug; 12():257. PubMed ID: 22897891
[TBL] [Abstract][Full Text] [Related]
11. Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation.
Corbett M; Duarte A; Llewellyn A; Altunkaya J; Harden M; Harris M; Walker S; Palmer S; Dias S; Soares M
Health Technol Assess; 2020 Aug; 24(39):1-248. PubMed ID: 32840478
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel KR; Ali MK; Zhou X; Ng BP; Jawanda S; Proia K; Zhang X; Gregg EW; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1557-1592. PubMed ID: 33534729
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of treatment of women aged 70 years and older with both osteopenia and microstructural deterioration.
Liew D; Chapurlat RD; Sornay-Rendu E; Lespessailles E; Peng Y; Seeman E
Bone; 2021 Jan; 142():115682. PubMed ID: 33039577
[TBL] [Abstract][Full Text] [Related]
14. Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany.
Kairys P; Frese T; Voigt P; Horn J; Girndt M; Mikolajczyk R
PLoS One; 2022; 17(1):e0262227. PubMed ID: 34986199
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic.
Zafarnejad R; Chen Q; Griffin PM
PLoS One; 2024; 19(3):e0299401. PubMed ID: 38478491
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes.
Guinan K; Beauchemin C; Tremblay J; Chalmers J; Woodward M; Tahir MR; Hamet P; Lachaine J
Can J Diabetes; 2021 Mar; 45(2):129-136. PubMed ID: 33032912
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.
Treharne C; Liu FX; Arici M; Crowe L; Farooqui U
Appl Health Econ Health Policy; 2014 Aug; 12(4):409-20. PubMed ID: 25017433
[TBL] [Abstract][Full Text] [Related]
18. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.
Schwartz NRM; Matrisian LM; Shrader EE; Feng Z; Chari S; Roth JA
J Natl Compr Canc Netw; 2021 Jun; 20(5):451-459. PubMed ID: 34153945
[TBL] [Abstract][Full Text] [Related]
19. Health care costs in people with diabetes and their association with glycemic control and kidney function.
McBrien KA; Manns BJ; Chui B; Klarenbach SW; Rabi D; Ravani P; Hemmelgarn B; Wiebe N; Au F; Clement F
Diabetes Care; 2013 May; 36(5):1172-80. PubMed ID: 23238665
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
